Solventum (NYSE:SOLV) Releases FY 2026 Earnings Guidance

Solventum (NYSE:SOLV) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share (EPS) guidance of 6.600-6.600 for the period, compared to the consensus estimate of 6.470. The company issued revenue guidance of -.

Solventum Stock Up 1.3%

Shares of SOLV stock traded up $0.88 on Wednesday, hitting $69.92. The stock had a trading volume of 932,944 shares, compared to its average volume of 1,213,756. The business has a 50 day moving average of $67.91 and a 200 day moving average of $74.51. The stock has a market cap of $12.12 billion, a price-to-earnings ratio of 7.88, a price-to-earnings-growth ratio of 1.10 and a beta of 0.59. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.23 and a quick ratio of 0.89. Solventum has a 12-month low of $62.38 and a 12-month high of $88.20.

Solventum (NYSE:SOLV) last announced its earnings results on Tuesday, May 5th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.35 by $0.13. The company had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. Solventum had a net margin of 18.69% and a return on equity of 25.26%. The firm’s revenue for the quarter was down 3.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.34 earnings per share. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, analysts expect that Solventum will post 6.5 EPS for the current year.

Analysts Set New Price Targets

SOLV has been the subject of a number of research analyst reports. UBS Group reiterated a “neutral” rating and issued a $78.00 target price on shares of Solventum in a research note on Wednesday. Wall Street Zen downgraded shares of Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. KeyCorp lifted their target price on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research note on Wednesday. Weiss Ratings reiterated a “hold (c)” rating on shares of Solventum in a research note on Tuesday, January 27th. Finally, Stifel Nicolaus set a $90.00 target price on shares of Solventum in a research note on Wednesday. Seven analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $85.91.

Insider Transactions at Solventum

In related news, Director Amy Mcbride Wendell bought 1,475 shares of the company’s stock in a transaction on Tuesday, March 10th. The stock was acquired at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the completion of the transaction, the director directly owned 5,039 shares in the company, valued at $342,803.17. This trade represents a 41.39% increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.24% of the stock is currently owned by insiders.

More Solventum News

Here are the key news stories impacting Solventum this week:

• Positive Sentiment: Q1 results beat expectations — SOLV reported $1.48 EPS vs. $1.35 consensus and revenue of $2.01B vs. $1.97B, showing better-than-expected profitability and margins. This is the primary catalyst for the rally. SOLV Tops Q1
• Positive Sentiment: Raised/firm guidance — management set FY2026 EPS at 6.600 (top of prior range), above consensus, and said organic sales and free cash flow targets remain intact — supports forward earnings visibility. Q1 Financial Results
• Positive Sentiment: Management commentary and call highlights point to margin momentum (wound care and sterilization demand cited) — suggests structural improvement in profitability beyond the quarter. Earnings Call Highlights
• Positive Sentiment: Technical upside — SOLV recently cleared both the 20‑day and 50‑day moving averages, a short-term bullish signal that can attract technical traders. 20-Day Breakout 50-Day Breakout
• Positive Sentiment: Buy-side support: BTIG reaffirmed a Buy with an $89 target — adds a sizable upside scenario for investors to consider. BTIG Reaffirmed
• Neutral Sentiment: Full call transcript and investor materials are available for deeper read — useful for modeling margins and guidance execution risk. Earnings Call Transcript
• Neutral Sentiment: Analyst consensus remains mixed / Hold on average — suggests market opinion is not uniformly bullish despite the beat. Consensus Recommendation
• Negative Sentiment: Wells Fargo cut its price target from $83 to $70 and set an “equal weight” rating — this downgrade introduces near-term resistance and could cap gains if other shops follow. Wells Fargo PT Cut

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Pacer Advisors Inc. raised its stake in shares of Solventum by 28.2% during the fourth quarter. Pacer Advisors Inc. now owns 17,149 shares of the company’s stock worth $1,359,000 after acquiring an additional 3,768 shares in the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in Solventum by 1,482.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 538 shares of the company’s stock valued at $43,000 after buying an additional 504 shares during the last quarter. Invesco Ltd. raised its holdings in Solventum by 3.4% during the 4th quarter. Invesco Ltd. now owns 2,930,010 shares of the company’s stock valued at $232,174,000 after buying an additional 96,236 shares during the last quarter. Corient Private Wealth LLC raised its holdings in Solventum by 8.3% during the 4th quarter. Corient Private Wealth LLC now owns 44,882 shares of the company’s stock valued at $3,334,000 after buying an additional 3,443 shares during the last quarter. Finally, CrossGen Wealth LLC bought a new stake in Solventum during the 4th quarter valued at $25,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.